William J Martin1, D Euan MacIntyre. 1. Department of Pharmacology, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ, USA. william_martin@merck.com
Abstract
OBJECTIVE: Review the historical and current evidence that suggests that activation of melanocortin receptors modulates erectile activity. METHODS: The available literature was reviewed. RESULTS: Melanocortin peptides derived from the pro-opiomelanocortin (POMC) precursor protein exert a host of diverse physiological effects in the periphery and in the CNS through interactions with one or more of the five cloned melanocortin receptors. Natural and synthetic melanocortin peptide agonists influence erectile and sexual function in a range of preclinical species. Emerging clinical evidence now suggests that the proerectile effects observed in preclinical species are evident in man as well. CONCLUSIONS: Preclinical and clinical results support the involvement of melanocortins in the modulation of erectile and sexual function. Current evidence indicates that the melanocortin 4 receptor subtype contributes to the proerectile effects observed with pan-receptor agonists. However, the putative receptor subtypes, pathways and mechanisms implicated in mediating the proerectile effects of melanocortins remain to be fully elucidated.
OBJECTIVE: Review the historical and current evidence that suggests that activation of melanocortin receptors modulates erectile activity. METHODS: The available literature was reviewed. RESULTS: Melanocortin peptides derived from the pro-opiomelanocortin (POMC) precursor protein exert a host of diverse physiological effects in the periphery and in the CNS through interactions with one or more of the five cloned melanocortin receptors. Natural and synthetic melanocortin peptide agonists influence erectile and sexual function in a range of preclinical species. Emerging clinical evidence now suggests that the proerectile effects observed in preclinical species are evident in man as well. CONCLUSIONS: Preclinical and clinical results support the involvement of melanocortins in the modulation of erectile and sexual function. Current evidence indicates that the melanocortin 4 receptor subtype contributes to the proerectile effects observed with pan-receptor agonists. However, the putative receptor subtypes, pathways and mechanisms implicated in mediating the proerectile effects of melanocortins remain to be fully elucidated.
Authors: Stephen H King; Alexander V Mayorov; Preeti Balse-Srinivasan; Victor J Hruby; Todd W Vanderah; Hunter Wessells Journal: Curr Top Med Chem Date: 2007 Impact factor: 3.295
Authors: Alex S Huang; Anne Beigneux; Zachary M Weil; Paul M Kim; Mark E Molliver; Seth Blackshaw; Randy J Nelson; Stephen G Young; Solomon H Snyder Journal: J Neurosci Date: 2006-03-08 Impact factor: 6.167
Authors: Shubh Sharma; Alastair S Garfield; Bhavik Shah; Patrick Kleyn; Ilia Ichetovkin; Ida Hatoum Moeller; William R Mowrey; Lex H T Van der Ploeg Journal: Molecules Date: 2019-05-16 Impact factor: 4.411